Metabolism Comparison Matrix
“Metabolic & NAD+ Research” is a catalogue grouping, not a single biochemical mechanism. The category contains a dinucleotide cofactor, peptides, a small-molecule enzyme inhibitor, a carnitine solution and a growth-hormone fragment analogue. The correct material depends on the experimental question.
Metabolism research matrix
| Material | Entity class | Representative research question | Main evidence caution |
|---|---|---|---|
| NAD+ 1000mg | Dinucleotide cofactor | Redox chemistry and NAD-consuming enzymes such as sirtuins, PARPs and CD38 | Do not convert pathway association into an anti-ageing or energy claim |
| MOTS-c 40mg | Mitochondria-derived peptide research entity | Metabolic signalling and stress-response pathways | Exact peptide form and preclinical model matter |
| SS-31 10mg | Mitochondria-targeting tetrapeptide research entity | Cardiolipin/membrane biophysics and mitochondrial protein interactions | Do not equate RUO material with a regulated elamipretide medicine |
| 5-Amino-1MQ 50mg | Small-molecule NNMT inhibitor research compound | NNMT-related metabolic flux in experimental models | Animal weight/metabolic endpoints are not a consumer outcome claim |
| L-Carnitine 600mg/ml | Small zwitterionic carnitine compound in a finished liquid formulation | Carnitine shuttle and long-chain fatty-acid transport | Finished-solution concentration/formulation evidence is product-specific |
| AOD9604 5mg | Synthetic hGH-fragment-related peptide research entity | Rodent metabolic and beta-adrenergic-signalling questions | Rodent body-weight/fat findings do not establish human weight management |
NAD+ is a biochemical cofactor, not a peptide
NAD+ participates in redox reactions and is consumed by several signalling-enzyme families. Its experimental handling and assay design therefore differ fundamentally from peptide products. See the NAD+ research overview.
MOTS-c and SS-31 ask different mitochondrial questions
MOTS-c literature focuses on mitochondria-derived peptide signalling and metabolic responses. SS-31 research focuses strongly on cardiolipin-rich membranes, membrane biophysics and mitochondrial protein interactions. Grouping them under “mitochondrial research” does not make their mechanisms or assay designs interchangeable.
5-Amino-1MQ and L-carnitine are not peptides
5-Amino-1MQ is studied as a small-molecule NNMT inhibitor. L-carnitine is part of the carnitine shuttle used for long-chain acyl-group transport. Their chemical identity, formulation and analytical methods differ from peptide workflows.
The analytical package also changes with the entity. NAD+/NADH redox-state assays, peptide sequence and mass assignments, small-molecule inhibitor characterisation, and a finished L-carnitine solution’s concentration/formulation are different measurement tasks. A chromatographic area percentage, identity spectrum or nominal label on one class should not be treated as equivalent to quantitative content or product-lot verification for another class. Use the method and units actually reported for the material in question, with the CoA-reading guide as a documentation framework.
AOD9604 belongs to a different evidence family
AOD9604 is a growth-hormone-fragment-related peptide studied in rodent metabolic models. Its category position does not make it a NAD-pathway compound or a substitute for the other entries.
How to select an experimental material
- Define the molecular process: redox cofactor, mitochondrial membrane, peptide signalling, enzyme inhibition or fatty-acid transport.
- Choose the material whose literature actually addresses that process.
- State the exact entity/form and model.
- Use product documentation for formulation and lot-specific evidence.
- Keep animal and cell endpoints separate from human outcome claims.
Research-use boundary
This matrix does not rank compounds for fat loss, anti-ageing, exercise performance, metabolic health or safety. It provides laboratory-research disambiguation only.